Key result
Proposed precision medicine guide outlines practical digoxin use in HFrEF despite declining prescriptions.
Why the study?
Despite being the oldest drug in continuous use for heart failure, digoxin prescriptions have sharply declined amid the advent of disease-modifying therapies and toxicity concerns.
How can digoxin be utilized in a precision medicine-based approach for heart failure with reduced ejection fraction?
How can digoxin be utilized in a precision medicine-based approach for heart failure with reduced ejection fraction?
This paper proposes a practical precision medicine-based guide for the use of digoxin in heart failure with reduced ejection fraction, addressing its declining use and toxicity concerns.
Answers are grounded in this paper and cite their sources.
Warrants precision-guided digoxin in symptomatic HFrEF; challenges fixed-dose paradigm and extends role beyond current guidelines.[[1]](https://www.abcheartfailure.org/article/digoxin-in-heart-failure-with-reduced-ejection-fraction-a-proposal-for-a-practical-precision-medicine-based-guide/)[[1]](https://www.abcheartfailure.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Germano Emílio Conceição‐Souza (2025) conducted a review in Heart Failure with Reduced Ejection Fraction. Digoxin was evaluated. Digoxin use in heart failure with reduced ejection fraction is addressed through a proposed practical precision medicine-based guide, despite its recent decline in prescriptions.
Synapse has enriched 10 related papers. Consider them for comparative context: